FI923495A - Peptidylderivat. - Google Patents

Peptidylderivat. Download PDF

Info

Publication number
FI923495A
FI923495A FI923495A FI923495A FI923495A FI 923495 A FI923495 A FI 923495A FI 923495 A FI923495 A FI 923495A FI 923495 A FI923495 A FI 923495A FI 923495 A FI923495 A FI 923495A
Authority
FI
Finland
Prior art keywords
group
alkyl
amino
alkenyl
hydrogen atom
Prior art date
Application number
FI923495A
Other languages
English (en)
Finnish (fi)
Other versions
FI923495A0 (fi
Inventor
John Robert Porter
Thomas Andrew Millican
John Richard Morphy
Nigel Robert Arnold Beeley
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026251A external-priority patent/GB9026251D0/en
Priority claimed from GB919110339A external-priority patent/GB9110339D0/en
Priority claimed from GB919110338A external-priority patent/GB9110338D0/en
Priority claimed from GB919112901A external-priority patent/GB9112901D0/en
Priority claimed from GB919112888A external-priority patent/GB9112888D0/en
Priority claimed from GB919115039A external-priority patent/GB9115039D0/en
Priority claimed from GB919115038A external-priority patent/GB9115038D0/en
Priority claimed from GB919115916A external-priority patent/GB9115916D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of FI923495A0 publication Critical patent/FI923495A0/fi
Publication of FI923495A publication Critical patent/FI923495A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
FI923495A 1990-12-03 1992-08-03 Peptidylderivat. FI923495A (fi)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB909026251A GB9026251D0 (en) 1990-12-03 1990-12-03 Netalloproteinase inhibitors
GB919110339A GB9110339D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919110338A GB9110338D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919112901A GB9112901D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919112888A GB9112888D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919115039A GB9115039D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115038A GB9115038D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115916A GB9115916D0 (en) 1991-07-23 1991-07-23 Metalloproteinase inhibitors
PCT/GB1991/002143 WO1992009565A1 (en) 1990-12-03 1991-12-03 Peptidyl derivatives

Publications (2)

Publication Number Publication Date
FI923495A0 FI923495A0 (fi) 1992-08-03
FI923495A true FI923495A (fi) 1992-08-03

Family

ID=27571285

Family Applications (2)

Application Number Title Priority Date Filing Date
FI923494A FI923494A (fi) 1990-12-03 1992-08-03 Peptidylderivat.
FI923495A FI923495A (fi) 1990-12-03 1992-08-03 Peptidylderivat.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI923494A FI923494A (fi) 1990-12-03 1992-08-03 Peptidylderivat.

Country Status (16)

Country Link
US (1) US5300501A (de)
EP (2) EP0489579B1 (de)
JP (2) JPH05503719A (de)
KR (2) KR927003521A (de)
AT (2) ATE120451T1 (de)
AU (2) AU652793B2 (de)
CA (2) CA2073510A1 (de)
DE (2) DE69108363T2 (de)
DK (1) DK0489579T3 (de)
ES (1) ES2069833T3 (de)
FI (2) FI923494A (de)
GB (2) GB2255340B (de)
GR (1) GR3015567T3 (de)
HU (3) HUT62263A (de)
NO (2) NO922968L (de)
WO (2) WO1992009565A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
EP0634998B1 (de) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0671911A4 (de) * 1992-11-25 1996-08-21 Merck & Co Inc Carboxypeptidyl-derivate als antidegenerative wirkstoffe.
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5652262A (en) * 1993-03-16 1997-07-29 British Biotech Pharmaceutical, Ltd. Hydroxamic acid derivatives as metalloproteinase inhibitors
AU6554294A (en) * 1993-04-07 1994-10-24 Glycomed Incorporated Synthetic matrix metalloprotease inhibitors and uses thereof
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69419473T2 (de) * 1993-04-27 2000-03-16 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
EP0712390B1 (de) * 1993-08-02 1998-12-09 Celltech Therapeutics Limited Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CN1049651C (zh) * 1994-01-20 2000-02-23 英国生物技术药物有限公司 金属蛋白酶抑制剂
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
AU2572295A (en) * 1994-05-28 1995-12-21 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB2303629B (en) * 1994-06-22 1998-09-02 British Biotech Pharm Hydroxamic acids and their use as metalloproteinase inhibitors
US5831004A (en) 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5857961A (en) * 1995-06-07 1999-01-12 Clarus Medical Systems, Inc. Surgical instrument for use with a viewing system
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
JP2000500761A (ja) 1995-11-23 2000-01-25 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
ES2195034T3 (es) * 1995-12-08 2003-12-01 Agouron Pharma Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
ATE220660T1 (de) 1996-09-10 2002-08-15 British Biotech Pharm Cytostatische hydroxamsäurederivate
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH10130217A (ja) * 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0887077A1 (de) * 1997-06-27 1998-12-30 Roche Diagnostics GmbH Verwendung von Azulenderivaten als Metalloproteaseinhibitoren
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
JP2001031637A (ja) * 1999-05-17 2001-02-06 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体
WO2000069812A1 (fr) * 1999-05-17 2000-11-23 Daiichi Fine Chemical Co., Ltd. Nouveaux dérivés d'acide hydroxamique
CO5210860A1 (es) 1999-10-01 2002-10-30 Hoffmann La Roche Nuevos derivados de pirimidina-2,4,6-triona
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
DK1406893T3 (da) 2001-06-15 2007-08-06 Vicuron Pharm Inc Bicykliske pyrrolidinforbindelser
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
WO2005090387A2 (en) * 2004-03-23 2005-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone h2a peptide derivatives and analogs and methods of use thereof
US7605132B2 (en) 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
WO2004060425A2 (en) * 2002-12-27 2004-07-22 Angiotech International Ag Compositions and methods of using collagen and mmpi
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
DE202010018378U1 (de) 2009-04-10 2016-04-07 Tufts Medical Center, Inc. PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)
DE102014206916A1 (de) 2014-04-10 2015-10-15 Wacker Chemie Ag Verfahren zur Ruthenium-katalysierten Umvinylierung von Carbonsäuren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5196412A (en) * 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds

Also Published As

Publication number Publication date
FI923495A0 (fi) 1992-08-03
GB2255339B (en) 1994-10-05
AU652596B2 (en) 1994-09-01
NO922967D0 (no) 1992-07-28
DE69108529D1 (de) 1995-05-04
HUT62263A (en) 1993-04-28
DE69108529T2 (de) 1995-11-30
DE69108363D1 (de) 1995-04-27
AU9017391A (en) 1992-06-25
KR927003520A (ko) 1992-12-18
GB9211714D0 (en) 1992-08-26
WO1992009564A1 (en) 1992-06-11
FI923494A0 (fi) 1992-08-03
KR927003521A (ko) 1992-12-18
EP0489579A1 (de) 1992-06-10
HU9202497D0 (en) 1992-10-28
NO922967L (no) 1992-09-24
HU9202498D0 (en) 1992-10-28
FI923494A (fi) 1992-08-03
JPH05503720A (ja) 1993-06-17
HUT61973A (en) 1993-03-29
NO922968D0 (no) 1992-07-28
EP0489577A1 (de) 1992-06-10
WO1992009565A1 (en) 1992-06-11
CA2073513A1 (en) 1992-06-04
GB9211715D0 (en) 1992-08-26
ATE120451T1 (de) 1995-04-15
AU652793B2 (en) 1994-09-08
GR3015567T3 (en) 1995-06-30
DE69108363T2 (de) 1995-08-31
GB2255339A (en) 1992-11-04
JPH05503719A (ja) 1993-06-17
AU9023391A (en) 1992-06-25
DK0489579T3 (da) 1995-06-12
GB2255340B (en) 1994-09-28
NO922968L (no) 1992-09-24
GB2255340A (en) 1992-11-04
EP0489577B1 (de) 1995-03-22
ES2069833T3 (es) 1995-05-16
ATE120182T1 (de) 1995-04-15
US5300501A (en) 1994-04-05
EP0489579B1 (de) 1995-03-29
CA2073510A1 (en) 1992-06-04

Similar Documents

Publication Publication Date Title
FI923494A (fi) Peptidylderivat.
DE3867572D1 (de) Benzothiazol-derivat und es als aktiven bestandteil enthaltendes antirheumatisches mittel.
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE3381964D1 (de) Dithio-verbindungen, diese enthaltende pharmazeutische praeparate und deren verwendung.
DK0387194T3 (da) N-Substituerede aminoalkandiphosphonsyrer
ES8702379A1 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
ATE497382T1 (de) Kosmetische oder pharmazeutische zubereitungen enthaltend 1,3,5-triazinderivate und zinkoxid
DE58902234D1 (de) Alpha-hydroxy-azolylethyloxirane und diese enthaltende fungizide.
DE3861545D1 (de) Aminoverbindungen und diese enthaltende fungizide.
DK363284A (da) Endo-8,8-dialkyl-8-azoniabicyclo/3.2.1/octan-6,7-exo-epoxy-3-alkylcarboxylatsalte, fremgangsmaade til fremstilling heraf og terapeutiske praeparater indeholdende disse
DK656889A (da) Azabicykliske derivater
MD122C2 (ro) Procedeu de obţinere a derivaţilor oxadiazolilalchilpurinei sau a sărurilor ei acide aditive farmacologic acceptabile
RU94043799A (ru) Производные эпи-эпибатиденов

Legal Events

Date Code Title Description
FD Application lapsed